Navigation Links
DFH Pharma to Collaborate with CiVentiChem to Develop Second-Generation HIV Maturation Inhibitor Drugs
Date:1/4/2012

GAITHERSBURG, Md., Jan. 4, 2012 /PRNewswire-iReach/ -- DFH Pharma, Inc., (DFH) a privately held specialty pharmaceutical company focused exclusively in the HIV-1 therapeutic space, announced today the selection of CiVentiChem, LLC to provide medicinal chemistry services to support DFH efforts to develop the next generation of HIV maturation inhibitor drugs. Maturation inhibitors are a novel class of antiretroviral drug candidates that inhibit HIV-1 replication by interfering with the maturation of the HIV-1 virus. 

The collaboration will allow DFH Pharma to expedite the discovery of 2nd generation maturation inhibitor drugs by utilizing CiVentiChem's extensive experience in the preparation and characterization of small molecule drug candidates. During 2012 DFH will work closely with CiVentiChem to extend recent successful efforts to discover new drug candidates with potent activity against all HIV strains, including those that proved resistant to the first-in-class maturation inhibitor, bevirimat. In addition to the preparation of new triterpene analogs, which form the basis for the current 2nd generation program, DFH plans to work with CiVentiChem to explore new chemical space with the goal of identifying additional classes of compounds with maturation inhibition activity.

"We are very excited to be working with CiVentiChem in the discovery of new 2nd generation HIV maturation inhibitors" said Dr. David Martin, DFH Pharma Chief Development Officer.  Dr. Martin continued, "The collaboration will allow DFH access to world-class medicinal chemists and help the Company to achieve its primary goal of returning this exciting class of HIV drug to the clinic".  Bhaskar Venepalli, Ph.D., President of CiVentiChem commented, "We are very pleased that DFH Pharma has selected CiVentiChem as its chemistry partner. We look forward to employing our va
'/>"/>

SOURCE DFH Pharma, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Thomson Scientific Publishes The Ones to Watch - A Quarterly Review of Phase Changes in the Pharmaceutical Pipeline
2. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
3. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
4. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
5. Clinical Trial Effectiveness: How Pharmas & Biotechs Save Cost with Savvy Investigator Management
6. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
7. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
8. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
9. Par Pharmaceutical Begins Shipment of Additional Dosage Strength of Generic TOPROL-XL(R)
10. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
11. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/21/2014)... 2014  Heated dialogue in recent months about the ... treatments to Gilead,s new hepatitis C drug Harvoni® – ... questioning what it means to put a price on ... And while drug pricing is one of the most ... a general business and ethical standpoint – it is ...
(Date:11/21/2014)... 2014 Clementia Pharmaceuticals, Inc. ... (EMA) has granted Orphan Medicinal Product Designation ... for the treatment of fibrodysplasia ossificans progressiva ... genetic disease characterized by painful, recurrent episodes ... abnormal bone formation. This process, known as ...
(Date:11/21/2014)... Nov. 20, 2014 /PRNewswire/-- CANTEL MEDICAL CORP. (NYSE: CMN ... Executive Officer, will be presenting at the 26 th ... Hotel in New York . The formal ... PM ET. In addition, Mr. Krakauer and Jorgen B. ... one-on-one meetings during the day. An audio ...
Breaking Medicine Technology:"The Price of Global Health" Tackles Worldwide Drug-Pricing Debate 2"The Price of Global Health" Tackles Worldwide Drug-Pricing Debate 3"The Price of Global Health" Tackles Worldwide Drug-Pricing Debate 4"The Price of Global Health" Tackles Worldwide Drug-Pricing Debate 5Clementia Pharmaceuticals Receives EMA Orphan Medicinal Product Designation for Palovarotene for the Treatment of Fibrodysplasia Ossificans Progressiva 2Clementia Pharmaceuticals Receives EMA Orphan Medicinal Product Designation for Palovarotene for the Treatment of Fibrodysplasia Ossificans Progressiva 3
... AstraZeneca (NYSE: AZN ) announced today that Judge Joseph ... that the substance patent protecting CRESTOR (RE37,314 – the ,314 patent) is valid ... committed by any Shionogi employee. The court also held the ,314 patent to ... , , ...
... June 29 Dr. Harry J. Guttman, Esq. , Of ... participant at the 2010 Central Regional Meeting of the American Chemical Society ...  The 2010 CeRMACS attracted over 400 participants and focused on small business ... , , ...
Cached Medicine Technology:CRESTOR® Patent Upheld By US Court 2CRESTOR® Patent Upheld By US Court 3Dr. Harry J. Guttman, Esq. Invited Speaker at 2010 Central Regional Meeting of the American Chemical Society 2
(Date:11/22/2014)... Recently, UWDress.com, a successful wedding dress shop, has released its ... order to prepare for the wedding season. All of them ... , UWDress.com is a reliable company that has many years ... items -- formal wedding guest attire. This new collection comes ... and princess. As one of the leading companies in the ...
(Date:11/22/2014)... New York, NY (PRWEB) November 22, 2014 ... Australia’s Therapeutics Goods Administration (TGA) approved it for ... Glutathione was approved and listed within the Therapeutic ... http://www.comlaw.gov.au/Details/F2014L01277 , Kyowa Hakko’s Setria® Glutathione ... Chem, a biotech specialist that sources and imports ...
(Date:11/22/2014)... PA (PRWEB) November 22, 2014 "My ... the pain caused by the machine," said an inventor ... she had to go back a second time because ... invention idea." , She developed the patent-pending MAMO EASY ... breast cancer. The design saves the patient from the ...
(Date:11/22/2014)... November 22, 2014 Lipitor lawsuits ( ... patients who allegedly developed Type 2 diabetes due to ... multidistrict litigation now underway in U.S. District Court, District ... court documents, the litigation will convene its next Status ... has directed Lead Counsel for Plaintiffs and Defendants to ...
(Date:11/22/2014)... 2014 The Sports Conflict Institute ... to its team of conflict resolution professionals. Baroff comes ... and referee. He has over 30 years experience as an ... “I'm very excited to connect with SCI and bring my ... to a program with a complete sports focus,” says Baroff. ...
Breaking Medicine News(10 mins):Health News:Formal Wedding Guest Attire Added to UWDress.com 2Health News:Setria® Glutathione Now Available in Australia 2Health News:Setria® Glutathione Now Available in Australia 3Health News:Lipitor Lawsuit Conference Scheduled for December, Bernstein Liebhard LLP Reports 2Health News:Lipitor Lawsuit Conference Scheduled for December, Bernstein Liebhard LLP Reports 3Health News:SCI Announces New Team Member Roy Baroff 2Health News:SCI Announces New Team Member Roy Baroff 3
... Health Management Systems,Inc. (HMS) announced today that it ... in Medford, Massachusetts, to provide coordination of,benefits services. ... than 150,000 MassHealth and Commonwealth Care members across,Massachusetts., ... will identify third party coverage for claims already ...
... CHARLOTTE, N.C., Dec. 12 CG Technology has ... better reflecting the depth,and breadth of services it ... high quality and standards of work, while focusing ... Carlisle & Gallagher Consulting Group (CG) is a ...
... 12 ATS Medical, Inc.,(Nasdaq: ATSI ), ... services, today announced that James L. Cox, M.D. ... Dr. Cox, reputation as a,preeminent authority in the ... that serves as the foundation for ATS 3f(R),tissue ...
... to six community organizations in ... underserved areas, WOODLAND HILLS, ... a total of $30,000 in end of,year donations to various food banks ... agencies in northern and,southern California to assist vulnerable populations., Blue Cross ...
... An improved understanding of the effects of regulation ... designed to advance entrepreneurship, according to a new ... for Entrepreneurship Public Policy report provides an overview ... system can discourage or encourage the entrepreneurial spirit. ...
... Dec. 11 Biodel Inc. (Nasdaq:,BIOD) today reported ... financial results, updated pipeline progress and disclosed 2008,objectives., ... public company, we advanced our pipeline,and achieved critical ... of Biodel. "The significant milestones reached include our,successful ...
Cached Medicine News:Health News:Network Health Awards Contract to HMS for Coordination of Benefits 2Health News:ATS Medical Appoints James L. Cox, M.D. as Medical Director 2Health News:ATS Medical Appoints James L. Cox, M.D. as Medical Director 3Health News:Blue Cross of California Gives $30,000 in Holiday Donations to Food Banks Throughout the State 2Health News:Rand study examines the effect of policy on entrepreneurship and small businesses 2Health News:Biodel Inc. Reports Fourth Quarter and Fiscal Year 2007 Financial Results 2Health News:Biodel Inc. Reports Fourth Quarter and Fiscal Year 2007 Financial Results 3Health News:Biodel Inc. Reports Fourth Quarter and Fiscal Year 2007 Financial Results 4Health News:Biodel Inc. Reports Fourth Quarter and Fiscal Year 2007 Financial Results 5Health News:Biodel Inc. Reports Fourth Quarter and Fiscal Year 2007 Financial Results 6Health News:Biodel Inc. Reports Fourth Quarter and Fiscal Year 2007 Financial Results 7Health News:Biodel Inc. Reports Fourth Quarter and Fiscal Year 2007 Financial Results 8Health News:Biodel Inc. Reports Fourth Quarter and Fiscal Year 2007 Financial Results 9
... 420 CPAP System includes the 420E Auto-CPAP ... can enjoy the advantages of the worlds ... devices. The GoodKnight 420E model records up ... includes other features of the 420S model. ...
Paediatric tubes have decreased sample volumes and are ideal for small childrens' veins and geriatric patients....
Safety Blood Collection Sets are supplied in three packaging variations, either with or without Luer Adapter and respectively a version with Luer Adapter and Tube Holder....
Simplicity and multi-directional retraction for a broad range of abdominal procedures...
Medicine Products: